Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $55.41 in the prior trading day, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $56.56, up 2.08%. In other words, the price has increased by $2.08 from its previous closing price. On the day, 0.71 million shares were traded. TARS stock price reached its highest trading level at $56.56 during the session, while it also had its lowest trading level at $54.7039.
Ratios:
Our goal is to gain a better understanding of TARS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Azamian Bobak R. sold 6,000 shares for $50.00 per share. The transaction valued at 300,000 led to the insider holds 818,106 shares of the business.
Azamian Bobak R. bought 6,000 shares of TARS for $300,000 on Aug 11 ’25. On Jun 17 ’25, another insider, Farrow Jeffrey S, who serves as the insider of the company, sold 13,608 shares for $40.42 each. As a result, the insider received 550,035 and left with 36,704 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2387629568 and an Enterprise Value of 2078932864. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.08 while its Price-to-Book (P/B) ratio in mrq is 7.18. Its current Enterprise Value per Revenue stands at 7.035 whereas that against EBITDA is -21.562.
Stock Price History:
The Beta on a monthly basis for TARS is 0.78, which has changed by 1.2154329 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $57.28, while it has fallen to a 52-week low of $25.14. The 50-Day Moving Average of the stock is 30.01%, while the 200-Day Moving Average is calculated to be 19.63%.
Shares Statistics:
The stock has traded on average 617.25K shares per day over the past 3-months and 748710 shares per day over the last 10 days, according to various share statistics. A total of 42.21M shares are outstanding, with a floating share count of 38.56M. Insiders hold about 8.65% of the company’s shares, while institutions hold 107.59% stake in the company. Shares short for TARS as of 1753920000 were 8136900 with a Short Ratio of 13.18, compared to 1751241600 on 8856844. Therefore, it implies a Short% of Shares Outstanding of 8136900 and a Short% of Float of 19.93.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Tarsus Pharmaceuticals Inc (TARS) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of $0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$1.44 and -$1.56 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is $0.03, with 3.0 analysts recommending between $1.39 and -$2.15.
Revenue Estimates
6 analysts predict $113.05M in revenue for the current quarter. It ranges from a high estimate of $118.92M to a low estimate of $109.93M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $48.12MFor the next quarter, 6 analysts are estimating revenue of $131.67M. There is a high estimate of $137.26M for the next quarter, whereas the lowest estimate is $124.24M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $437.18M, while the lowest revenue estimate was $415.16M, resulting in an average revenue estimate of $425.61M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $607.94M in the next fiscal year. The high estimate is $715.08M and the low estimate is $464.91M.
